Latest action: Received in the Senate and Read twice and referred to the Committee on the Judiciary.
Originating chamber has voted to pass. Sent to the other chamber.
The House voted to pass the bill. It now moves to the Senate, which repeats the committee referral and floor-vote process.
Next: Passed Both Chambers
Conference committee (if versions differ), then the President
Establishes the National Organization for Rare Respiratory Ailments to coordinate research and treatment.
The problem
Rare respiratory diseases affect many Americans but receive limited research funding and coordinated care because they are individually uncommon and scattered across medical systems.
The proposal
Creates NORRA as a federal organization to coordinate research, improve patient care coordination, establish treatment standards, and increase awareness for rare respiratory conditions.
The impact
Patients with rare respiratory diseases, medical researchers, healthcare providers, and federal agencies involved in health coordination will experience changes in funding, care availability, and research focus.
Patients with rare respiratory diseases often struggle to find doctors who understand their condition. A coordinating organization could connect patients with specialists and share information between hospitals. This could reduce diagnosis time and improve treatment quality.
Rare diseases often get little research attention because each affects few people individually. A dedicated organization could pool resources and attract researchers to these conditions. This could lead to new treatments that currently don't exist.
Many people with rare respiratory diseases don't know about support resources or research opportunities. NORRA could help patients find information and connect with others facing the same conditions. This could improve outcomes and quality of life.
Different hospitals may treat rare conditions differently without clear guidelines. NORRA could establish best practices and treatment standards. This could ensure patients get consistent, evidence-based care wherever they live.
Creating a new federal organization requires funding from taxpayers. The cost of staff, research, and operations could be significant depending on the organization's size. Taxpayers would bear this expense during budget constraints.
Adding a new federal agency could create administrative delays and complexity. Coordination between NORRA and existing health agencies might create confusion about who is responsible. Too much bureaucracy could slow down research and patient help.
If NORRA receives limited funding, it may not significantly improve outcomes for all rare respiratory diseases. Resources might go to administrative costs rather than actual research. The organization could disappoint patients if it cannot deliver meaningful improvements.
Existing federal agencies and private organizations already work on rare diseases. NORRA might duplicate efforts already underway. This could waste resources instead of creating new value or efficiency.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Other bills in this policy area
HR 10764
Executive Settlement Review Act
HR 8352
Criminal History Access Act of 2026
S 32
LACA
HR 10389
Survivor’s Voice Protection Act
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.